Glatiramer acetate (Copaxone®) therapy for multiple sclerosis

Research output: Contribution to journalReview article

56 Citations (Scopus)

Abstract

Glatiramer acetate (GA) (Copaxone®) is a worldwide-approved drug for the treatment of relapsing multiple sclerosis (MS), an autoimmune disease of the CNS. The drug is a synthetic copolymer with an amino acid composition based on the structure of myelin basic protein, one of the autoantigens implicated in the pathogenesis of MS and experimental autoimmune encephalomyelitis (EAE). Developed initially as a "tool" to study EAE, the drug unexpectedly inhibited disease and was subsequently developed for the treatment of MS. The drug has been shown in controlled clinical trials to significantly reduce relapse rate and progression of disability in MS with long-term efficacy, remarkable safety, and tolerability. Efficacy as measured by magnetic resonance imaging parallels its clinical benefits as manifested by a reduction in gadolinium-enhancing lesions and brain atrophy. The mechanism of action of the drug in humans is believed to involve the induction of glatiramer-reactive regulatory cells, including CD4+ and CD8+ T-cells. Glatiramer-reactive Th2 cells are believed to enter the brain and, through cross-reactivity with myelin antigens, produce bystander suppression, antiinflammatory effects, and neuroprotection.

Original languageEnglish (US)
Pages (from-to)245-255
Number of pages11
JournalPharmacology and Therapeutics
Volume98
Issue number2
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Multiple Sclerosis
Pharmaceutical Preparations
Autoimmune Experimental Encephalomyelitis
Bystander Effect
Therapeutics
Th2 Cells
Myelin Basic Protein
Controlled Clinical Trials
Autoantigens
Gadolinium
Brain
Myelin Sheath
Autoimmune Diseases
Atrophy
Anti-Inflammatory Agents
Magnetic Resonance Imaging
Glatiramer Acetate
T-Lymphocytes
Safety
Antigens

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology

Keywords

  • Experimental autoimmune encephalomyelitis
  • Glatiramer acetate
  • Magnetic resonance imaging
  • Multiple sclerosis

Cite this

@article{8c486b3f9be04b12af25196b554e0d40,
title = "Glatiramer acetate (Copaxone{\circledR}) therapy for multiple sclerosis",
abstract = "Glatiramer acetate (GA) (Copaxone{\circledR}) is a worldwide-approved drug for the treatment of relapsing multiple sclerosis (MS), an autoimmune disease of the CNS. The drug is a synthetic copolymer with an amino acid composition based on the structure of myelin basic protein, one of the autoantigens implicated in the pathogenesis of MS and experimental autoimmune encephalomyelitis (EAE). Developed initially as a {"}tool{"} to study EAE, the drug unexpectedly inhibited disease and was subsequently developed for the treatment of MS. The drug has been shown in controlled clinical trials to significantly reduce relapse rate and progression of disability in MS with long-term efficacy, remarkable safety, and tolerability. Efficacy as measured by magnetic resonance imaging parallels its clinical benefits as manifested by a reduction in gadolinium-enhancing lesions and brain atrophy. The mechanism of action of the drug in humans is believed to involve the induction of glatiramer-reactive regulatory cells, including CD4+ and CD8+ T-cells. Glatiramer-reactive Th2 cells are believed to enter the brain and, through cross-reactivity with myelin antigens, produce bystander suppression, antiinflammatory effects, and neuroprotection.",
keywords = "Experimental autoimmune encephalomyelitis, Glatiramer acetate, Magnetic resonance imaging, Multiple sclerosis",
author = "Suhayl Dhib-Jalbut",
year = "2003",
month = "5",
day = "1",
doi = "https://doi.org/10.1016/S0163-7258(03)00036-6",
language = "English (US)",
volume = "98",
pages = "245--255",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "2",

}

Glatiramer acetate (Copaxone®) therapy for multiple sclerosis. / Dhib-Jalbut, Suhayl.

In: Pharmacology and Therapeutics, Vol. 98, No. 2, 01.05.2003, p. 245-255.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Glatiramer acetate (Copaxone®) therapy for multiple sclerosis

AU - Dhib-Jalbut, Suhayl

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Glatiramer acetate (GA) (Copaxone®) is a worldwide-approved drug for the treatment of relapsing multiple sclerosis (MS), an autoimmune disease of the CNS. The drug is a synthetic copolymer with an amino acid composition based on the structure of myelin basic protein, one of the autoantigens implicated in the pathogenesis of MS and experimental autoimmune encephalomyelitis (EAE). Developed initially as a "tool" to study EAE, the drug unexpectedly inhibited disease and was subsequently developed for the treatment of MS. The drug has been shown in controlled clinical trials to significantly reduce relapse rate and progression of disability in MS with long-term efficacy, remarkable safety, and tolerability. Efficacy as measured by magnetic resonance imaging parallels its clinical benefits as manifested by a reduction in gadolinium-enhancing lesions and brain atrophy. The mechanism of action of the drug in humans is believed to involve the induction of glatiramer-reactive regulatory cells, including CD4+ and CD8+ T-cells. Glatiramer-reactive Th2 cells are believed to enter the brain and, through cross-reactivity with myelin antigens, produce bystander suppression, antiinflammatory effects, and neuroprotection.

AB - Glatiramer acetate (GA) (Copaxone®) is a worldwide-approved drug for the treatment of relapsing multiple sclerosis (MS), an autoimmune disease of the CNS. The drug is a synthetic copolymer with an amino acid composition based on the structure of myelin basic protein, one of the autoantigens implicated in the pathogenesis of MS and experimental autoimmune encephalomyelitis (EAE). Developed initially as a "tool" to study EAE, the drug unexpectedly inhibited disease and was subsequently developed for the treatment of MS. The drug has been shown in controlled clinical trials to significantly reduce relapse rate and progression of disability in MS with long-term efficacy, remarkable safety, and tolerability. Efficacy as measured by magnetic resonance imaging parallels its clinical benefits as manifested by a reduction in gadolinium-enhancing lesions and brain atrophy. The mechanism of action of the drug in humans is believed to involve the induction of glatiramer-reactive regulatory cells, including CD4+ and CD8+ T-cells. Glatiramer-reactive Th2 cells are believed to enter the brain and, through cross-reactivity with myelin antigens, produce bystander suppression, antiinflammatory effects, and neuroprotection.

KW - Experimental autoimmune encephalomyelitis

KW - Glatiramer acetate

KW - Magnetic resonance imaging

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0037408259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037408259&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/S0163-7258(03)00036-6

DO - https://doi.org/10.1016/S0163-7258(03)00036-6

M3 - Review article

C2 - 12725872

VL - 98

SP - 245

EP - 255

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 2

ER -